Available courses

2025 Manuscript Peer Review for Physicians Postgraduate Press, Inc. (The Journal of Clinical Psychiatry | The Primary Care Companion for CNS Disorders)

2025 Manuscript Peer Review for Physicians Postgraduate Press, Inc. (The Journal of Clinical Psychiatry | The Primary Care Companion for CNS Disorders)

This CME activity is eligible for credit only to those who complete a Manuscript Peer Review and obtain and Enrollment code. 

CME credit for physicians or CE participation credit for nonphysicians is awarded for reviews submitted in a timely manner and in recognition of the learning that takes place during a manuscript review.

To be awarded credit and receive a certificate for this activity, peer-review learners must have completed their peer review in a timely manner and have provided constructive criticism to the author and Editor. The peer reviewer must complete the following Evaluation form to claim credit.

You will be awarded 3.00 AMA PRA Category 1 CreditTM for this activity. The ACCME allows up to 15.00 AMA PRA Category 1 CreditTM for peer review to be claimed each year.

Learning Objective

We anticipate learners will make improvements in their ability to critically review research manuscripts, as well as incorporate new research findings into their own practice as appropriate. 

Available Credit

  • 3.00 AMA PRA Category 1 Credit™
  • 3.00 Participation
Assessing Progress in FSHD Treatment Options: Unraveling Challenges and Measuring Outcomes

Assessing Progress in FSHD Treatment Options: Unraveling Challenges and Measuring Outcomes

Program Introduction

Join Leo Wang and Maya Hatch for an insightful journey into the world of Facioscapulohumeral Muscle Dystrophy (FSHD), covering its etiology, clinical presentations, and the complexities of assessing treatment outcomes in clinical trials. Key focuses include the innovative Reachable Workspace (RWS) metric for functional assessment, the impact of current clinical trials, and emerging therapeutic targets. Discussions will also highlight biomarker insights, disease mechanisms like DUX4 regulation, and future strategies for FSHD management. Don’t miss this opportunity to gain insights from experts shaping the future of FSHD research and care, along with perspective from a real-world patient living with FSHD.

Learning Objectives

  • Evaluate the use of RWS as an outcome measure for FSHD clinical trials to measure disease progression, impact on ADLs, and effect of therapy
  • Discuss the mechanism of FSHD disease that leads to challenges in DUX4 biomarker detection

Available Credit

  • 1.00 AMA PRA Category 1 CreditTM
  • 1.00 Participation
Alzheimer's Disease: New Paths to Treatment

Alzheimer's Disease: New Paths to Treatment

Program Introduction

Alzheimer’s Disease (AD) is a debilitating condition marked by amyloid plaques and neurofibrillary tangles in the brain, affecting over 6 million Americans—a number expected to nearly double in the next 30 years [Alzheimer’s Association 2023]. Early detection and prevention of plaque buildup are crucial in combating the disease. Recent advances in biomarker technology are reshaping diagnosis and treatment. This session will cover key biomarkers for early screening, evaluate approved and investigational therapies, and explore methods for early-stage detection, including cognitive tests and imaging. Join us to stay at the forefront of Alzheimer’s care and research.

Learning Objectives

  • Recognize the safety and efficacy of novel therapies that are approved as well as investigational  therapies in late-stage development in Alzheimer’s disease
  • Assess opportunities to screen for early-stage Alzheimer’s disease including various administration methods, cognitive assessments and imaging

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation

Evaluating the Old and New in Alzheimer’s Disease: Today’s Options for Improving Diagnosis and Treatment

Evaluating the Old and New in Alzheimer’s Disease: Today’s Options for Improving Diagnosis and Treatment

Program Introduction

This program brings together leading experts to explore advancements in the diagnosis and treatment of Alzheimer’s disease (AD). Presented by Marc E. Agronin, MD, R. Scott Turner, PhD, MD, and Susan Scanland, MSN, this program addresses key challenges and solutions in AD care. Topics include strategies for early detection and diagnosis through cognitive assessments, neuroimaging, and biomarker analysis; the role of novel and investigational disease-modifying therapies and the integration of therapeutic approaches, including FDA-approved treatments and nonpharmacologic interventions. The session emphasizes the importance of multidisciplinary management and shared decision-making with patients and caregivers to create comprehensive and effective care plans.

Learning Objectives

  • Identify biomarkers in screening for Alzheimer’s disease and in continual assessment of symptoms
  • Recognize the safety and efficacy of novel therapies that are approved as well as investigational therapies in late-stage development in Alzheimer’s disease
  • Assess opportunities to screen for early-stage Alzheimer’s disease including various administration methods, cognitive assessments and imaging

Available Credit

  • 1.0 AMA PRA Category 1 Credit™
  • 1.0 Participation

Staying Up to Date in Perinatal Depression: Pathophysiology and Treatment Research

Staying Up to Date in Perinatal Depression: Pathophysiology and Treatment Research

Program Introduction

This educational activity, presented by Dr. Deligiannidis, Dr. Vega, and Dr. Smith, offers clinicians an essential update on perinatal depression (PND), including its pathophysiology, diagnosis, and treatment options. With a focus on the latest research and therapeutic advancements, this session highlights the significant impact of timely diagnosis and the risks of delayed intervention.

Participants will explore the neurobiological underpinnings of PND, including mechanisms such as altered GABAergic neurotransmission and the roles of neuroactive steroids like allopregnanolone. The presentation also reviews evidence-based approaches, covering both traditional antidepressants (SSRIs, SNRIs, TCAs) and innovative treatments like brexanolone and zuranolone. Practical insights on real-world applications, including considerations for the post-COVID era, provide clinicians with actionable knowledge to enhance care for patients affected by PND.

Learning Objectives

  • Identify appropriate best practices for the diagnosis of PDP
  • Implement evidence-based current therapies for patients with PDP

Available Credit

  • 1.00 AMA PRA Category 1 CreditTM
  • 1.00 Participation

Neuropsychiatric Complications of Parkinson’s Disease Psychosis

Neuropsychiatric Complications of Parkinson’s Disease Psychosis

Program Introduction

Join us for a dynamic one-hour CME activity on Parkinson’s Disease Psychosis (PDP) with top experts Mark F. Lew, MD, and Jennifer Hui, MD. Unlock the latest best practices for diagnosing PDP and implementing cutting-edge therapies. The session kicks off with a deep dive into Parkinson’s Disease, covering its prevalence, motor and nonmotor symptoms, and the unique challenges of PDP. Next, master the intricacies of recognizing and diagnosing PDP with the newest diagnostic criteria and screening tools. Finally, conquer PDP treatment and management strategies, including behavioral approaches, medication adjustments, and safe antipsychotic options. Plus, gain invaluable insights from the caregiver of a real-world patient with PDP, providing a firsthand perspective on managing this complex condition. Boost your clinical expertise and transform patient care with this essential update on managing Parkinson’s Disease Psychosis.

Learning Objectives

  • Identify appropriate best practices for the diagnosis of PDP
  • Implement evidence-based current therapies for patients with PDP

Available Credit

  • 1.00 AMA PRA Category 1 CreditTM
  • 1.00 Participation

Advancements in Understanding Facioscapulohumeral Muscular Dystrophy (FSHD) and What Clinically Meaningful Outcomes Look Like

Advancements in Understanding Facioscapulohumeral Muscular Dystrophy (FSHD) and What Clinically Meaningful Outcomes Look Like

Program Introduction

Delve into the cutting-edge advancements in Facioscapulohumeral Muscular Dystrophy (FSHD) alongside the dynamic duo of Dr. Leo H. Wang and Dr. Maya N. Hatch in this symposium recorded at the 2024 MDA Clinical & Scientific Conference Summit. Positioned as the third most prevalent muscular dystrophy, FSHD stands as a genetic enigma with intricate roots, showcasing a progressive saga of asymmetrical muscle weakness. Initially targeting the facial and shoulder muscles before spreading its grip onto the extremities, this disorder's clinical narrative presents a formidable challenge in quantifying outcomes. It's an imperative moment to unearth dependable and sensitive metrics for clinical trials, navigating the labyrinthine landscape of FSHD. Acquire invaluable insights into mastering daily functionalities, tackling complications head-on, and remain abreast of the latest breakthroughs in establishing rock-solid measures for gauging progress.

Learning Objectives

  • Evaluate the use of RWS as an outcome measure for FSHD clinical trials and translate changes in RWS to clinically meaningful outcomes
  • Discuss the mechanism of FSHD disease that leads to challenges in DUX4 biomarker detection

Available Credit

  • 1.00 AMA PRA Category 1 CreditTM
  • 1.00 Participation

All courses